ZD1694 (Tomudex): A new thymidylate synthase inhibitor with activity in colorectal cancer
- 31 August 1995
- journal article
- review article
- Published by Elsevier in European Journal Of Cancer
- Vol. 31 (7-8) , 1277-1282
- https://doi.org/10.1016/0959-8049(95)00166-g
Abstract
No abstract availableKeywords
This publication has 13 references indexed in Scilit:
- ‘Tomudex’ (ZD1694) : A novel thymidylate synthase inhibitor with clinical antitumour activity in a range of solid tumoursAnnals of Oncology, 1996
- Mechanisms of acquired resistance to the quinazoline thymidylate synthase inhibitor ZD1694 (Tomudex) in one mouse and three human cell linesBritish Journal of Cancer, 1995
- Preclinical and clinical aspects of biomodulation of 5-fluorouracilCancer Treatment Reviews, 1994
- The measurement of polyglutamate metabolites of the thymidylate synthase inhibitoR, ICI D1694, in mouse and human cultured cellsBiochemical Pharmacology, 1993
- The biochemical pharmacology of the thymidylate synthase inhibitor, 2-desamino-2-methyl-N10-propargyl-5,8-dideazafolic acid (ICI 198583)Biochemical Pharmacology, 1991
- The pharmacokinetics of the quinazoline antifolate ICID 1694 in mice and ratsCancer Chemotherapy and Pharmacology, 1991
- Quinazoline antifolate thymidylate synthase inhibitors: alkyl, substituted alkyl, and aryl substituents in the C-2 positionJournal of Medicinal Chemistry, 1990
- Quinazoline antifolates inhibiting thymidylate synthase: 2-desamino derivatives with enhanced solubility and potencyJournal of Medicinal Chemistry, 1989
- Modulation of anti-metabolite effectsBiochemical Pharmacology, 1984
- A potent antitumour quinazoline inhibitor of thymidylate synthetase: Synthesis, biological properties and therapeutic results in micePublished by Elsevier ,1981